SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for Ernexa Therapeutics Inc. (ERNA, ERNAW) (CIK 0000748592) (ERNA) — Apr 15, 2016

Ernexa Therapeutics Inc. (ERNA, ERNAW) (CIK 0000748592)
Date: April 15, 2016 · CIK: 0000748592 · Accession: 0000000000-16-072350

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

Date
April 7, 2016
Author
/s/ Celeste M. Murphy for
Form
UPLOAD
Company
Ernexa Therapeutics Inc. (ERNA, ERNAW) (CIK 0000748592)

Letter

Mail Stop 3720 April 15 , 2016 Ram Krishnan Chief Executive Officer NTN Buzztime, Inc. 2231 Rutherford Road, Suite 200 Carlsbad, California

Re: NTN Buzztime, Inc. Preliminary Proxy on Schedule 14A Filed April 7, 2016 File No. 001 -11460

Dear Mr. Krishnan :

We have completed our review of your filing. We remind you that our comment or the changes to disclosure in response to our comment do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,
/s/ Celeste M. Murphy for

Show Raw Text
Mail Stop 3720

April 15 , 2016

Ram Krishnan
Chief Executive Officer
NTN Buzztime, Inc.
2231 Rutherford Road, Suite 200
Carlsbad, California

Re: NTN Buzztime, Inc.
 Preliminary Proxy on Schedule 14A
Filed April 7, 2016
File No. 001 -11460

Dear Mr. Krishnan :

We have completed our review of your filing.  We remind you that our comment or the
changes to disclosure in response to our comment do not foreclose the Commission from taking
any action with respect to the company or the filing and the company may not assert staff
comments as a defense in any proceeding initiated by the Commission or any person under the
federal securities laws of the United States.  We urge all persons who are responsible for the
accuracy and adequacy of the disclosure in the filing  to be certain that the filing  includes the
information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,

 /s/ Celeste M. Murphy for

 Larry Spirgel
Assistant Direc tor
 AD Office 11 – Telecommunications